Synthesis of budesonide conjugates and their anti-inflammatory effects: a preliminary study
Authors Yan Y, Wang P, Li R, Sun Y, Zhang R, Huo C, Xing J, Dong Y
Received 26 October 2018
Accepted for publication 25 January 2019
Published 19 February 2019 Volume 2019:13 Pages 681—694
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Georgios Panos
Yan Yan,1,2 Pengchong Wang,2 Ruiying Li,3 Ying Sun,2 Rui Zhang,2 Chuanchuan Huo,2 Jianfeng Xing,2 Yalin Dong1
1Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China; 2Department of Pharmaceutics, School of Pharmacy, Xi’an Jiaotong University, Xi’an, Shaanxi, China; 3Department of Clinical Medicine, College of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, China
Purpose: Budesonide (Bud) is a nonhalogenated glucocorticoid with high anti-inflammatory potency and low systemic side effects. However, the poor water solubility of Bud affects its dissolution and release behavior, thus influencing its anti-inflammatory effect. This study was aimed at synthesizing and evaluating novel conjugates of Bud, hoping to increase the anti-inflammatory activity of Bud by improving its water solubility.
Materials and methods: Seven novel Bud conjugates (3a–3g) were designed and synthesized in this study. Besides, the equilibrium solubility, cell viability, in vitro and in vivo anti-inflammatory activity, and the hydrolysis behavior of the conjugates in different pH solutions, rat and human plasma, and rat lung homogenate were studied in detail.
Results: As compared to Bud, the equilibrium solubility of 3a, 3c, and 3e was significantly increased; 3a, 3b, and 3c significantly inhibited the interleukin-6 production in lipopolysaccharide-induced A549 cells; 3a and 3e could significantly decrease the xylene-induced ear edema; and 3a and 3c were gradually and slowly hydrolyzed into Bud in the alveolar fluid and lung homogenate and broken down quickly in plasma.
Conclusion: The amino acid ester compounds budesonide-21-glycine ester (3a) and budesonide-21-alanine ester (3c) were selected as potential conjugates of Bud. This study would provide a theoretical and an experimental basis for the in vivo process of glucocorticoids and the treatment of inflammatory diseases.
Keywords: budesonide, glucocorticoid, anti-inflammatory effect, equilibrium solubility, hydrolysis behavior
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]